Join
Live feed
·
PRReleasevia Quantisnow
Context Therapeutics Inc. logo

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

ByQuantisnow·Wall Street's wire, on your screen.
CNTX· Context Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CNTX (Context Therapeutics Inc.) and more on Quantisnow.